| Autor: |
Belenkov YN; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University)., Tsvetkova OA; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University)., Privalova EV; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University)., An GV; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University)., Ilgisonis IS; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University)., Voronkova OO; I.M. Sechenov's First Moscow State Medical University of Ministry of Health (Sechenov University). |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 2019 Jun 25; Vol. 59 (6), pp. 48-55. Date of Electronic Publication: 2019 Jun 25. |
| DOI: |
10.18087/cardio.2019.6.n458 |
| Abstrakt: |
Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality. Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients' mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
